Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease
about
sameAs
Effects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patientsDrug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activityEffect of renal impairment on the pharmacokinetics of bupropion and its metabolitesMechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseasesPharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.ESRD impairs nonrenal clearance of fexofenadine but not midazolam.Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolismUsing drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?Consequences of renal failure on non-renal clearance of drugs.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment.Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients.Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.
P2860
Q34726696-A7A8158F-BCC1-450B-90F6-48DB8605001FQ35048793-BAEB06F2-0607-45F4-8F76-6F2FFB85E430Q35826402-7179F060-8A90-4CFA-813A-E47FD7B1D289Q35826495-6F95183E-146E-4CEA-B346-94823A21F600Q35827674-E60BA962-CB42-4B54-AE46-FF0C474883E8Q36024598-D8AD2C4A-3F15-4676-A494-2606365B29FDQ36040772-F1E6ADE0-9D9D-4023-95F5-4A107BE0FA1AQ36125450-452D1D43-A82A-4987-B79F-B1BD48FA5AA5Q36326210-9AC91143-BB10-468E-A8E4-0030E6AD3EC7Q36733922-52D846D3-B7D3-4764-B80F-BD5A96427ED8Q36885663-4DA9CE20-B1E9-47C8-B6DD-BF0A1ACCBAE9Q36916904-5036DEB1-3C1B-4620-BE72-657A56AB1ADAQ37042128-716B98A8-FEF7-4480-A437-8E84833862C4Q37076544-21471A8F-ACF4-48F1-B0C4-266C75C9C8DCQ37157896-9516A383-05D2-4628-80C3-0A06B9E98223Q37367679-755D7389-1029-4227-B604-33A53F46DE1AQ37391009-24D331E3-EE83-4531-B459-0E804A6B68A5Q37462071-549B7180-4691-4E12-AD6D-8AB86969D9FFQ37622756-739582E1-F25C-4329-ACC3-D2353ACE5FA6Q37645239-A7F91C65-E67F-4099-AA2D-2CB45F841CA3Q37733572-594D856F-FC81-4A1D-A823-7B4B0EE7718BQ38214827-E3D2282D-668F-420A-A06E-F4846FFA3698Q38222867-102E45E9-82A1-4570-B1F2-D92D543C0F43Q41328717-856859D8-5B2B-4388-BE74-846E47D06802Q43488121-E0F140C7-1533-4820-895D-3EAF20C5348EQ43841175-8738282E-AE94-487C-B5CF-6F4B8E292EB9Q44770176-FFB0CBB2-2042-4B58-BCC7-319DCD920301Q46542223-58E0848B-F479-4FEA-A2C8-C11FCEB0CC15Q46807643-0B1830F6-97A6-45BD-8164-30E6D09BF188Q47853973-89D9395B-9AC9-4DC9-8E09-2EB0E7A9DB94
P2860
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Characterization of hepatic cy ...... s with end-stage renal disease
@ast
Characterization of hepatic cy ...... s with end-stage renal disease
@en
Characterization of hepatic cy ...... s with end-stage renal disease
@nl
type
label
Characterization of hepatic cy ...... s with end-stage renal disease
@ast
Characterization of hepatic cy ...... s with end-stage renal disease
@en
Characterization of hepatic cy ...... s with end-stage renal disease
@nl
prefLabel
Characterization of hepatic cy ...... s with end-stage renal disease
@ast
Characterization of hepatic cy ...... s with end-stage renal disease
@en
Characterization of hepatic cy ...... s with end-stage renal disease
@nl
P2093
P3181
P1476
Characterization of hepatic cy ...... s with end-stage renal disease
@en
P2093
Andrew E Briglia
Chetan S Karyekar
Donna S Hanes
Lucy Stackiewicz
Matthew R Weir
Natalie D Eddington
Paul D Light
William L Henrich
P304
P3181
P356
10.1016/S0009-9236(03)00056-0
P407
P577
2003-05-01T00:00:00Z